Marzia Capelletti

14.4k citations

66 papers · 5.2k · 3 hit papers · h-index 27

Impact in

Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations

Papers in

Oncology 34
- Lung Cancer Research Studies 13
- HER2/EGFR in Cancer Research 10
Molecular Biology 29
- Cancer therapeutics and mechanisms 7

Co-authors: Pasi A. Jänne (29 shared papers)Dalia Ercan (12 shared papers)Nathanael S. Gray (9 shared papers)Michael J. Eck (5 shared papers)Cai‐Hong Yun (3 shared papers)Kwok‐Kin Wong (5 shared papers)Andrea Ardizzoni (11 shared papers)James G. Christensen (4 shared papers)
Journals: Blood (11 papers)Journal of Clinical Oncology (10 papers)Cancer Research (7 papers)Clinical Cancer Research (6 papers)Journal of Thoracic Oncology (3 papers)
Partner nations: United States Italy France

In The Last Decade

Marzia Capelletti

66 papers receiving 5.1k citations

Marzia Capelletti's Hit Papers

align trajectories log scale

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor 2010 · 604 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 New England Journal of Medicine
2009 Nature
2008 Journal of Clinical Oncology

Peers

Countries citing papers authored by Marzia Capelletti

Since Specialization

Citations

This map shows the geographic impact of Marzia Capelletti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marzia Capelletti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marzia Capelletti more than expected).

Fields of papers citing papers by Marzia Capelletti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marzia Capelletti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marzia Capelletti. The network helps show where Marzia Capelletti may publish in the future.

Co-authors

The 25 scholars most cited alongside Marzia Capelletti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marzia Capelletti Line = papers co-authored together Marzia Capelletti links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature ·Wenjun Zhou, Dalia Ercan, Liang Chen, Cai‐Hong Yun, Danan Li, Marzia Capelletti, Alexis B. Cortot, Lucian R. Chirieac, Roxana E. Iacob, Robert F. Padera, John R. Engen, Kwok‐Kin Wong, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne Hit paper breakdown →	2009	785
2	Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ neu –Positive Metastatic Breast Cancer Journal of Clinical Oncology ·Antonino Musolino, Nadia Naldi, Beatrice Bortesi, Debora Pezzuolo, Marzia Capelletti, Gabriele Missale, Diletta Laccabue, Alessandro Zerbini, Roberta Camisa, Giancarlo Bisagni, Tauro Maria Neri, Andrea Ardizzoni Hit paper breakdown →	2008	745
3	Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor New England Journal of Medicine ·James E. Butrynski, David R. D’Adamo, Jason L. Hornick, Paola Dal Cin, Cristina R. Antonescu, Suresh C. Jhanwar, Marc Ladanyi, Marzia Capelletti, Scott J. Rodig, Nikhil H. Ramaiya, Eunice L. Kwak, Jeffrey W. Clark, Keith D. Wilner, James G. Christensen, Pasi A. Jänne, Robert G. Maki, George D. Demetri, Geoffrey I. Shapiro Hit paper breakdown →	2010	604
4	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors Clinical Cancer Research ·Dalia Ercan, Hwan Geun Choi, Cai‐Hong Yun, Marzia Capelletti, Ting Xie, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne	2015	291
5	The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers Cancer Research ·Takaaki Sasaki, Katsuhiro Okuda, Wei Zheng, James E. Butrynski, Marzia Capelletti, Liping Wang, Nathanael S. Gray, Keith D. Wilner, James G. Christensen, George D. Demetri, Geoffrey I. Shapiro, Scott J. Rodig, Michael J. Eck, Pasi A. Jänne	2010	254
6	Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance Proceedings of the National Academy of Sciences ·Neil Johnson, Shawn F. Johnson, Wei Yao, Yu-Chen Li, Young-Eun Choi, Andrea J. Bernhardy, Yifan Wang, Marzia Capelletti, Kristopher A. Sarosiek, Lisa A. Moreau, Dipanjan Chowdhury, Anneka Wickramanayake, Maria I. Harrell, Joyce F. Liu, Alan D. D’Andrea, Alexander Miron, Elizabeth M. Swisher, Geoffrey I. Shapiro	2013	197
7	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS Cell ·Chiara Ambrogio, Jens Köhler, Zhi-Wei Zhou, Haiyun Wang, Raymond M. Paranal, Jiaqi Li, Marzia Capelletti, Cristina Caffarra, Shuai Li, Qi Lv, Sudershan Reddy Gondi, John C. Hunter, Jia Lu, Roberto Chiarle, David Santamarı́a, Kenneth D. Westover, Pasi A. Jänne	2018	188
8	Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial Journal of Clinical Oncology ·Pasi A. Jänne, Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Thomas E. Stinchcombe, Lin Gu, Marzia Capelletti, Martin J. Edelman, Miguel A. Villalona‐Calero, Robert A. Kratzke, Everett E. Vokes, Vincent A. Miller	2012	188
9	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor Oncogene ·Dalia Ercan, Kreshnik Zejnullahu, Kimio Yonesaka, Yun Xiao, Marzia Capelletti, Andrew M. Rogers, Eugene Lifshits, Alyssa Brown, Charles Lee, James G. Christensen, David J. Kwiatkowski, Jeffrey A. Engelman, Pasi A. Jänne	2010	181
10	Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway Cancer Research ·Alexis B. Cortot, Claire E. Repellin, Takeshi Shimamura, Marzia Capelletti, Kreshnik Zejnullahu, Dalia Ercan, James G. Christensen, Kwok‐Kin Wong, Nathanael S. Gray, Pasi A. Jänne	2012	163
11	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer Cancer Discovery ·Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal Rosen, Nathanael S. Gray, Kwok‐Kin Wong, Pasi A. Jänne	2015	159
12	A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer Cancer Cell ·Frederick H. Wilson, Cory M. Johannessen, Federica Piccioni, Pablo Tamayo, Jong Wook Kim, Eliezer M. Van Allen, Steven M. Corsello, Marzia Capelletti, Antonio Calles, Mohit Butaney, Tanaz Sharifnia, Stacey B. Gabriel, Jill P. Mesirov, William C. Hahn, Jeffrey A. Engelman, Matthew Meyerson, David E. Root, Pasi A. Jänne, Levi A. Garraway	2015	130
13	Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer British Journal of Cancer ·L. Flores, David W. Kindelberger, Azra H. Ligon, Marzia Capelletti, Mario V. Fiorentino, Massimo Loda, Edmund S. Cibas, Pasi A. Jänne, Ian E. Krop	2010	114
14	EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma Clinical Cancer Research ·Mai He, Marzia Capelletti, Khédoudja Nafa, Cai‐Hong Yun, Maria E. Arcila, Vincent A. Miller, Michelle S. Ginsberg, Binsheng Zhao, Mark G. Kris, Michael J. Eck, Pasi A. Jänne, Marc Ladanyi, Geoffrey R. Oxnard	2011	109
15	Intratumoral Heterogeneity in EGFR -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition Cancer Research ·Margaret Soucheray, Marzia Capelletti, Inés Pulido, Yanan Kuang, Cloud P. Paweletz, Jeffrey H. Becker, Eiki Kikuchi, Chunxiao Xu, Tarun B. Patel, Fátima Al‐Shahrour, Julián Carretero, Kwok‐Kin Wong, Pasi A. Jänne, Geoffrey I. Shapiro, Takeshi Shimamura	2015	103
16	BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study The Breast ·Antonino Musolino, Maria Angela Bella, Beatrice Bortesi, Maria Michiara, Nadia Naldi, Paola Zanelli, Marzia Capelletti, Debora Pezzuolo, Roberta Camisa, M Savi, Tauro Maria Neri, Andrea Ardizzoni	2007	101
17	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors Cancer Research ·Takayuki Kosaka, Junko Tanizaki, Raymond M. Paranal, Hideki Endoh, Christine Lydon, Marzia Capelletti, Claire E. Repellin, Jihyun Choi, Atsuko Ogino, Antonio Calles, Dalia Ercan, Amanda J. Redig, Magda Bahcall, Geoffrey R. Oxnard, Michael J. Eck, Pasi A. Jänne	2017	100
18	Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma Clinical Cancer Research ·Marzia Capelletti, Michael Dodge, Dalia Ercan, Peter S. Hammerman, Seung-Il Park, Young Tae Kim, Hidefumi Sasaki, David M. Jablons, Doron Lipson, Lauren Young, Phil Stephens, Vincent A. Miller, Neal I. Lindeman, Kiara J. Munir, William G. Richards, Pasi A. Jänne	2014	79
19	Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer Clinical Cancer Research ·Curtis R. Chong, Magda Bahcall, Marzia Capelletti, Takayuki Kosaka, Dalia Ercan, Taebo Sim, Lynette M. Sholl, Mizuki Nishino, Bruce E. Johnson, Nathanael S. Gray, Pasi A. Jänne	2016	67
20	Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines Biochemical Pharmacology ·Silvia La Monica, Maricla Galetti, Roberta Alfieri, Andrea Cavazzoni, Andrea Ardizzoni, Marcello Tiseo, Marzia Capelletti, Matteo Goldoni, Sara Tagliaferri, Antonio Mutti, Claudia Fumarola, Mara Bonelli, Daniele Generali, Pier Giorgio Petronini	2009	67

About Marzia Capelletti

Marzia Capelletti is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Pathology and Forensic Medicine, having authored 66 papers that have together received 5.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (13 papers), HER2/EGFR in Cancer Research (10 papers), Immunotherapy and Immune Responses (9 papers), Cancer Genomics and Diagnostics (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Cancer therapeutics and mechanisms (7 papers) and Neuroendocrine Tumor Research Advances (7 papers). The work is most often cited by research in Oncology (2.9k citations), Pulmonary and Respiratory Medicine (2.6k citations), Cancer Research (816 citations), Molecular Biology (2.5k citations) and Radiology, Nuclear Medicine and Imaging (642 citations). Marzia Capelletti has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Pasi A. Jänne, Dalia Ercan, Nathanael S. Gray, Michael J. Eck, Cai‐Hong Yun, Kwok‐Kin Wong, Andrea Ardizzoni, James G. Christensen, Tauro Maria Neri and Roberta Camisa. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Marzia Capelletti

Impact in

Papers in i

In The Last Decade

Marzia Capelletti

Marzia Capelletti's Hit Papers

Peers

Countries citing papers authored by Marzia Capelletti

Fields of papers citing papers by Marzia Capelletti

All Works

About Marzia Capelletti

Explore authors with similar magnitude of impact

Papers in